2019
DOI: 10.4274/mjima.2018.30
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Epidemiology and Clinical Characteristics of Metallo-beta-lactamase Producing Pseudomonas aeruginosa Isolates

Abstract: Introduction:In this study, we aimed to determine the epidemiological properties of metallo-beta-lactamase-producing Pseudomonas aeruginosa (MBL-PA) isolates and to investigate the relationship between the presence of MBL-PA and patient morbidity and mortality. Materials and Methods: The study included carbapenem-resistant P. aeruginosa isolates recovered from various clinical specimens of 334 patients in Karadeniz Technical University Faculty of Medicine Hospital, a 900-bed university hospital in Trabzon, Tur… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 28 publications
(62 reference statements)
0
1
0
Order By: Relevance
“…Cephalosporin antibiotics were the conventional treatment in the clinic, but we found the top 3 predominant bacteria had very high resistance rates to most cephalosporin antibiotics (above 50%), except for Cefoperazone/Sulbactam (44.5%). According to other research [12], β-lactam antibiotics have been improved, with some new drugs FDA approved in recent years that were very effective, such as Ceftazidime-Avibactam, Ceftolozane/Tazobactam, Dalbavancin, etc. However, because bacteria evolve very rapidly, these new upgraded drugs may be ineffective on the mutant bacteria.…”
Section: Discussionmentioning
confidence: 99%
“…Cephalosporin antibiotics were the conventional treatment in the clinic, but we found the top 3 predominant bacteria had very high resistance rates to most cephalosporin antibiotics (above 50%), except for Cefoperazone/Sulbactam (44.5%). According to other research [12], β-lactam antibiotics have been improved, with some new drugs FDA approved in recent years that were very effective, such as Ceftazidime-Avibactam, Ceftolozane/Tazobactam, Dalbavancin, etc. However, because bacteria evolve very rapidly, these new upgraded drugs may be ineffective on the mutant bacteria.…”
Section: Discussionmentioning
confidence: 99%